Welcome to KodaKoda's Weekly Immunology News. I'm so glad you're tuning in today because we have a packed episode full of fascinating science spanning gut bacteria, cancer vaccines, viral immunity, preterm birth, and so much more. Whether you're a scientist yourself or just someone who loves learning about how our bodies fight disease, this episode has something for you. Let's dive right in.
We're starting today with a story about a bacterium that lives in your gut and eats mucus for breakfast. The paper is titled Unique adaptations in sulfatases underpin colonic mucin degradation by Akkermansia muciniphila, published on July 27th 2026 in Nature Microbiology. The first author is Debajit Dey from the Department of Biology at the University of York in the UK.
Now if you've been following gut health research at all, you've probably heard of Akkermansia muciniphila. It's one of the most talked-about bacteria in the human gut, and for good reason. It lives in the mucus layer that coats the inside of your colon, and it uses that mucus as its main food source. But here's where it gets interesting. That mucus, which scientists call colonic mucin, is not easy to digest. It's heavily decorated with sugar molecules called glycans, and many of those sugars have sulfate groups attached to them, making them especially tough to break down.
So the question the researchers were asking was this: how exactly does Akkermansia muciniphila pull this off? And what role do enzymes called carbohydrate sulfatases play in the process?
To answer that, Debajit Dey and the team used a combination of in vitro digestion assays, which means they tested the enzymes in a controlled lab setting outside of living organisms, along with proteomics, which is the large-scale study of proteins, and structural biology, which lets scientists see the three-dimensional shapes of molecules.
Here's what they found. Two sulfatases in particular, called Amuc1755 and Amuc0953, have some really unusual and rare features that are specifically suited to handling the sulfated sugar structures found in mucin. These enzymes are more modular than you'd expect, meaning they're built from multiple functional parts, and one of those parts is a completely new type of domain that had never been described before, which the researchers identified as a mucin-binding domain.
They also found that the size of the glycoprotein matters. When Akkermansia muciniphila was grown on colonic mucin as its sole carbon source, smaller glycoproteins, which are proteins with sugar chains attached, were particularly important for the bacterium's growth.
The team then did mutational analysis and localization studies to figure out where in the bacterial cell these desulfation events actually happen. Desulfation is the process of removing those sulfate groups from the sugars. They found that the removal of sulfate from a sugar called N-acetyl-D-glucosamine happened in the periplasm, which is a compartment inside the bacterial cell wall. But the removal of sulfate from another sugar called D-galactose happened both outside the cell and in the periplasm.
Why does any of this matter for your health? Well, Akkermansia muciniphila has consistently been associated with positive health outcomes, including better metabolic health and a lower risk of inflammatory bowel disease. But if this bacterium over-forages the mucus layer, it can actually contribute to disease. This study helps clarify the molecular details of exactly how this bacterium interacts with your gut lining, which is a key step toward understanding when it helps and when it might not.
Next up, we're moving into antiviral territory. The paper is titled Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2. It was published on July 27th 2026 in Nature Communications. The first author is Maximilian Sandmann from the Department of Biochemistry and Molecular Cell Biology at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany.
So let's set the scene here. When SARS-CoV-2 infects your cells, your immune system fights back in part by deploying a process called ADP-ribosylation. This is essentially a way your body's enzymes tag viral proteins with a molecule called ADP-ribose, and it's a signal that can interfere with the virus's ability to replicate. The virus, however, has a countermeasure. It carries a protein domain called Mac1, which is a macrodomain, and Mac1 can remove those ADP-ribose tags. So it's basically the virus erasing the immune system's graffiti. This makes Mac1 a really appealing drug target.
The researchers tested a range of compounds based on ADP and ADP-ribose, which are closely related molecules, to see which ones could effectively block Mac1. They measured how tightly these compounds bind to the enzyme and used a technique called cocrystallization, where you grow crystals of the protein with the drug molecule already docked inside it, and then use X-ray diffraction to see exactly how the drug fits. This helped them build what's called a structure-activity relationship, which is basically a map of which molecular features make a drug work better or worse.
And they found some really important things. First, you can improve how well a compound blocks Mac1 by swapping out a part of the ADP-ribose molecule called the distal ribose and replacing it with a small alkyl group. Alternatively, you can swap out a nitrogen atom on the adenine ring for a carbon atom. Both changes improve potency.
Using these insights, they developed a compound called beta-methyl-GS-441524-diphosphate, which inhibits Mac1 at nanomolar concentrations. That is an extremely low concentration, meaning it's very potent. And importantly, it shows more than a thousand-fold selectivity for the viral Mac1 over similar human enzymes called MacroD1 and MacroD2, which is crucial because you don't want your drug accidentally shutting down your own cellular machinery.
The team then added chemical masking groups to make the compound more cell-permeable, turning it into what's called a prodrug. A prodrug is a compound that gets converted into its active form once it's inside the cell. This prodrug inhibited SARS-CoV-2 in cell culture with an EC50 of 0.06 micromolar, while showing low cytotoxicity with a CC50 of greater than 50 micromolar. In plain terms, it killed the virus effectively at doses that didn't harm human cells. They then further modified it to improve stability, resulting in an EC50 of 0.03 micromolar. This is early-stage research, but it's a really promising step toward new antiviral drugs.
Now let's talk about a case study that reads almost like a medical thriller. The paper is titled Personalized Phage Therapy in an ICU Patient with Polymicrobial Pulmonary Infections, a case from a single-arm trial. Published July 27th 2026 in Nature Communications. The first author is Yongxin Shi from the Department of Critical Care Medicine at Shanghai Public Health Clinical Center, Fudan University in Shanghai, China.
Phage therapy is one of the most exciting and also most complicated frontiers in infectious disease medicine. Bacteriophages, or phages for short, are viruses that specifically infect and kill bacteria. In an era where antibiotic resistance is becoming a genuine crisis, phages offer a potential alternative or complement to traditional antibiotics. But this case shows just how complicated that can get in practice.
The patient was a 40-year-old man in the ICU who developed what's called a ventilator-associated infection, an infection that occurs in patients on mechanical ventilators. And it wasn't just one infection. He had sequential pulmonary infections caused by three different multidrug-resistant bacteria: Acinetobacter baumannii, Klebsiella pneumoniae, and Stenotrophomonas maltophilia. These are some of the most feared pathogens in hospital settings because they are resistant to many of our available antibiotics.
The medical team administered seven rounds of tailored phage therapy, sometimes targeting one pathogen at a time, sometimes two simultaneously, always alongside antibiotics. The results were mixed but ultimately encouraging. Acinetobacter baumannii was completely eradicated. That's a major win. But Klebsiella pneumoniae and Stenotrophomonas maltophilia showed a pattern of cyclical clearance and recurrence, meaning they'd be knocked down and then come back. This happened because of strain replacement, where one strain is cleared but a different strain takes over, and because of phage resistance, where the bacteria evolve to evade the phages.
Despite the complexity, phage therapy had measurable benefits. Bacterial load decreased. Fever came down. The patient's procalcitonin and IL-6 levels, both of which are markers of inflammation and infection, also dropped. Pulmonary inflammation improved. White blood cell counts and C-reactive protein, though, were less responsive. No severe adverse events were reported.
After six months, the patient was weaned from the ventilator and discharged. The authors emphasize that phage therapy provided transient but meaningful control, extending the window for intervention and reducing reliance on high-level antibiotics. This is a powerful illustration of both the promise and the complexity of personalized phage therapy.
Let's shift now to cancer immunology. The next paper is titled The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice. Published July 27th 2026 in Nature Communications. The first author is Jin Muk Kang from the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals Rainbow Babies and Children's Hospital in Cleveland, Ohio.
So here's the big idea. Dendritic cells are like the commanders of your immune system. They're the ones that capture foreign material, process it, and then present it to T cells to trigger an immune response. For decades, scientists have been trying to use dendritic cells as the basis for cancer vaccines. The concept is elegant: take a patient's dendritic cells, load them up with tumor antigens, which are proteins specific to cancer cells, inject them back, and let the immune system do the rest. The problem is that tumor antigens are often poorly immunogenic, meaning they don't trigger a strong enough immune response on their own. And another bottleneck is getting strong CD4-positive T helper cell responses, which are essential for orchestrating and sustaining anti-tumor immunity.
PROTEXI is the platform they developed to address this. Here's the clever twist: instead of using some generic helper antigen, they included CD4-positive T cell epitopes from the SARS-CoV-2 Spike protein. Why? Because a huge proportion of the human population now has immune memory against the Spike protein, either from COVID-19 infection or vaccination. By incorporating Spike epitopes into the dendritic cell vaccine, they're essentially hijacking pre-existing antiviral memory to provide powerful T helper support.
In mouse models of melanoma and breast cancer, PROTEXI significantly reduced tumor growth and improved survival. It promoted robust T cell infiltration into what the researchers called immune-cold tumors, which are tumors that normally don't attract many immune cells and are therefore harder to treat. The vaccine also increased cytotoxic T cell responses through something called epitope spreading, where the immune response broadens beyond the original targets, and it activated genes associated with optimal function in dendritic cells, NK cells, and T cells.
PROTEXI also performed well when combined with other immunotherapy agents in models of therapy-resistant tumors. And in a humanized mouse model of melanoma, PROTEXI combined Spike-derived CD4 epitopes with CD8-restricted antigens called PRAME and MAGE-A3, and significantly reduced tumor burden.
This is a really elegant idea. It's early-stage, in mice, but it opens up a really exciting avenue of research.
Our next paper takes us into the realm of pregnancy immunology, specifically the devastating problem of spontaneous preterm birth. The paper is titled Immunological maladaptation preceding spontaneous preterm birth in human pregnancies, published July 27th 2026 in Nature Communications. The first author is Ina Stelzer from the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University in Stanford, California.
Preterm birth, defined as birth before 37 weeks of gestation, is the leading cause of neonatal mortality and morbidity worldwide. And the sobering truth is that the majority of spontaneous preterm births occur without any identifiable clinical warning signs. We don't know they're coming until they happen.
What we do know is that the maternal immune system undergoes dramatic and carefully orchestrated changes throughout a normal pregnancy. Immune tolerance toward the fetus has to be balanced with the ability to fight infections. When this balance is disrupted, it can have serious consequences. But the question has always been: can we detect immune dysregulation early enough to actually do something about it?
This study used a nested case-control design within a low-risk, population-based pregnancy cohort. They looked at blood from mothers who went on to have preterm births versus mothers who delivered at full term, and they tracked immune markers across all three trimesters.
The findings are striking. Abnormal immune adaptation preceded spontaneous preterm birth by weeks to months, and it could discriminate preterm birth cases from term controls with an area under the receiver operating characteristic curve of 0.7. An AUROC of 0.7 is not perfect, but it's meaningfully better than chance and suggests real diagnostic potential.
In terms of what the immune differences looked like: during the first and second trimesters, immune cells from preterm birth mothers showed enhanced responses to something called an adrenergic stimulus, which is a signal related to stress hormones. Then in the third trimester, those same mothers showed increased production of pro-inflammatory cytokines. Cytokines are signaling proteins that drive inflammation, and elevated pro-inflammatory cytokines late in pregnancy are associated with labor, including premature labor.
The transcriptome analysis, which is a large-scale examination of gene expression, of CD4-positive T cells from the second trimester revealed that in preterm birth pregnancies, these cells had a Th17-skewed phenotype and were responsive to neuroactive proteins. Th17 cells are a subtype of helper T cells associated with inflammation. The connection to neuroactive proteins is fascinating and adds a neuroimmunological dimension to this story.
The authors describe this as a multi-omics resource, meaning it combines multiple types of biological data, that could serve as a foundation for developing early screening tools and preventive interventions for spontaneous preterm birth.
Now let's talk about a really intriguing paper about how RNA modifications control T cell behavior in the context of cancer. The title is Blocking the m6Am methyltransferase PCIF1 releases STAT1-mediated Th1 immunity to potentiate cancer immunotherapy. Published July 22nd 2026 in Nature Communications. The first author is Jiansong Huang from the Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine in Shanghai, China.
So this paper is about a type of RNA modification called m6Am. You've probably heard of epigenetics, which is about chemical modifications to DNA that influence gene expression without changing the DNA sequence itself. Well, epitranscriptomics is the equivalent for RNA, and it's a rapidly growing field. m6Am stands for N6 2-prime-O-dimethyladenosine, and it's a modification that can be placed on messenger RNA molecules to influence how efficiently those RNAs get translated into protein.
The enzyme responsible for adding m6Am modifications is called PCIF1. The team found that in naive T cells, m6Am levels are high, and PCIF1 keeps the cells in a quiescent state, meaning they're resting and not activated. When T cells get activated, m6Am levels drop dynamically. This suggests that m6Am and PCIF1 are part of a regulatory system that helps keep T cells quiet until they're needed.
The researchers generated mice with a T-cell-specific PCIF1 knockout, meaning PCIF1 was deleted only in T cells. These mice showed potent tumor suppression. The mechanism turned out to involve enhanced Th1 differentiation. Th1 cells are a subset of CD4-positive helper T cells that are particularly good at fighting tumors and intracellular infections. The enhanced Th1 response also amplified NK cell cytotoxicity, meaning natural killer cells became more effective at killing tumor cells.
The molecular mechanism is this: PCIF1 places m6Am modifications on the messenger RNA for STAT1, which is a key transcription factor that drives Th1 differentiation. These m6Am marks suppress STAT1 translation, meaning less STAT1 protein gets made. When PCIF1 is deleted or downregulated during activation, the brakes come off, STAT1 gets translated more efficiently, and Th1 polarization is accelerated.
Even more excitingly, the researchers identified Suramin as a pharmacological inhibitor of PCIF1. Suramin is actually an existing drug that has been around for a long time and has been used for other purposes. Here it disrupted m6Am modification, boosted Th1 responses, and suppressed tumor growth in mouse models. This identifies the PCIF1-m6Am-STAT1 axis as a new potential target for cancer immunotherapy.
Our next paper is about how cancer immunotherapy works, and specifically why it sometimes fails, at the level of tumor-associated macrophages. The paper is titled Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition. Published July 27th 2026 in Nature Communications. The first author is Yueyun Pan from the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet in Stockholm, Sweden.
Tumor-associated macrophages, or TAMs, are a major component of the tumor microenvironment. Unfortunately, in many tumors, TAMs adopt an immunosuppressive phenotype, meaning they actually help the tumor evade immune destruction rather than fighting it. Targeting TAMs therapeutically has become a major research focus.
This study explored a combination approach using two antibodies: anti-MARCO, which targets a scavenger receptor on the surface of immunosuppressive macrophages, and anti-PD-L1, which is an immune checkpoint inhibitor that prevents tumor cells from switching off T cells. The researchers used mouse models to investigate how effective this combination was and what determined success or failure.
They found that effective immunotherapy with this combination requires a functional endosomal pattern recognition machinery. Specifically, they showed that endosomal Toll-like receptors, particularly TLR9, are essential. Toll-like receptors are sensors of the innate immune system that detect molecular patterns associated with pathogens or cellular damage. TLR9 senses unmethylated CpG DNA, which is a pattern commonly found in bacterial and viral DNA.
The mechanism they uncovered is this: TLR9 preconditions macrophages to respond to the anti-MARCO treatment by regulating the transcription of inflammasome components. The inflammasome is a protein complex that senses danger signals and triggers an inflammatory response. When TLRs are absent, TAMs remain unresponsive to anti-MARCO treatment and retain their immunosuppressive phenotype, basically ignoring the drug.
This is a really important finding because it tells us that the efficacy of immunotherapy can depend on the innate immune signaling state of macrophages within the tumor. And it suggests that targeting TLR pathways could be a strategy to sensitize tumors that are currently resistant to immunotherapy.
Next, let's look at the heart. The paper is titled Macrophage adenylyl cyclase 7 protects against myocardial ischemia reperfusion injury in male mice. Published July 27th 2026 in Nature Communications. The first author is Guofang Xia from the Department of Cardiology at Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital in Shanghai, China.
When someone has a heart attack, doctors restore blood flow to the heart as quickly as possible, often through a procedure called percutaneous coronary intervention. But paradoxically, restoring blood flow can itself cause damage to the heart muscle. This is called ischemia reperfusion injury, and it's a major clinical challenge. Inflammation plays a big role in this injury, and cardiac macrophages are key orchestrators of that inflammatory response.
Using spatial transcriptomics, which maps gene expression across tissue sections, and flow cytometry to analyze cell populations, the researchers identified an enzyme called adenylyl cyclase 7, or ADCY7, as a macrophage-specific regulator that influences how severe ischemia reperfusion injury is.
They confirmed ADCY7 expression in patient samples and then established a macrophage depletion and reconstitution model in mice. When macrophages lacked ADCY7, ischemia reperfusion injury got significantly worse and cardiac function was impaired, but only in male mice. When ADCY7 was overexpressed in macrophages, the injury was attenuated. Macrophages without ADCY7 also showed increased leukocyte infiltration and more pro-inflammatory cytokine production.
The mechanistic story is elegant. ADCY7 generates cyclic AMP, which activates protein kinase A. Protein kinase A then inhibits the nuclear translocation of NF-kappa-B, which is a master transcription factor that drives inflammatory gene expression. So ADCY7 essentially keeps a brake on the inflammatory response in macrophages.
The researchers also developed a photoactivated adenylyl cyclase system, which is a light-activated tool that can boost cyclic AMP production on demand, and showed that it alleviated cardiac inflammation and ischemia reperfusion injury. This is a beautiful example of basic immunology informing potential therapeutic strategies for cardiovascular disease.
Let's stay with signaling but zoom into a more molecular level. The paper is titled PLCbeta enzymes are recruited to the plasma membrane in macrophages by both Gbeta-gamma and Galpha-q. Published August 4th 2026 in the Proceedings of the National Academy of Sciences. The first author is Maria Falzone from the Laboratory of Molecular Neurobiology and Biophysics at The Rockefeller University in New York.
PLCbeta enzymes, which stands for phospholipase C-beta, are critical signaling proteins in immune cells. Their job is to cleave a lipid molecule called PIP2 from the plasma membrane, producing two important second messengers: IP3 and DAG. IP3 triggers the release of calcium from intracellular stores, and DAG activates protein kinase C. Together, these signals regulate a broad range of cellular responses, including immune cell activation.
PLCbeta enzymes are regulated by G protein-coupled receptor signaling, specifically through two types of G protein subunits: Gbeta-gamma and Galpha-q. These G proteins are released when certain receptors on the cell surface get activated.
Here's an interesting puzzle that the paper addresses: PLCbeta enzymes are soluble proteins, meaning they float in the aqueous environment inside cells. But their substrate, PIP2, is a lipid embedded in the membrane. So how do the enzymes get to their substrate when they need to act? The answer is membrane recruitment, meaning the enzymes translocate to the plasma membrane upon stimulation.
The researchers used macrophages as their model system, which is appropriate because PLCbeta signaling is essential in macrophages for responses to infection and tissue injury. Using total internal reflection fluorescence microscopy and stimulated emission depletion microscopy, two advanced imaging techniques, they showed that most of the PLCbeta3 protein in macrophages sits away from the plasma membrane at rest. But upon stimulation with receptors coupled to either Galpha-i or Galpha-q type G proteins, PLCbeta3 rapidly recruits to the plasma membrane.
Importantly, they demonstrated that both Gbeta-gamma and Galpha-q are capable of independently recruiting PLCbeta to the membrane. This updates our model of how these enzymes are regulated and suggests that the local concentrations of receptors, G proteins, and PLCbeta determine the strength and character of the signaling response. For macrophage biologists, this is an important mechanistic clarification.
Let's move from the cell membrane to a much bigger scale: the ecology of food production and infectious disease. The paper is titled Accelerating Campylobacter zoonosis in the Anthropocene. Published August 11th 2026 in the Proceedings of the National Academy of Sciences. The first author is Oakem Kyne from the Ineos Oxford Institute for Antimicrobial Research at the University of Oxford in the United Kingdom.
Campylobacter jejuni is the leading bacterial cause of gastroenteritis in the world. You've almost certainly heard of food poisoning from undercooked chicken, and Campylobacter is very often the culprit. This bacterium is a zoonotic pathogen, meaning it normally lives in animals and can jump to humans. Chickens are the primary reservoir.
This study takes a sweeping, evolutionary, and ecological view of how intensive poultry farming has changed the landscape of Campylobacter transmission. The researchers analyzed 2747 genomes from chickens and wild birds and used phylogenetic reconstructions to trace the history of host transitions, meaning when did Campylobacter strains move from one type of bird host to another.
The findings are alarming. Since 1900, there has been an estimated 100-fold increase in chicken-to-wild-bird host transitions compared to pre-domestication levels. After 1960, which is roughly when industrial poultry farming took off globally, chicken-associated lineages expanded dramatically and pathogen effective population sizes rose sharply. The effective population size is a genetic measure that reflects how diverse and numerous the pathogen population is.
The researchers also used model simulations to show that expanding, high-density chicken populations can act as ecological pathogen sponges, absorbing and amplifying diverse strains while sustaining high prevalence and coinfection rates. And genome-wide association analyses showed that strains adapted to the chicken niche frequently pick up genes linked to oxidative stress resistance, metal homeostasis, motility, and antimicrobial resistance. These are all traits that make the pathogen more fit and harder to control.
This paper paints a sobering picture of how human agricultural practices are directly reshaping the evolution and spread of a major human pathogen, with real implications for public health and antimicrobial resistance.
Now let's return to cancer immunology with a paper focused on how cancer cells hide from immune surveillance. The paper is titled GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer. Published July 27th 2026 in Cell Reports. The first author is Lili Qian from the Department of Obstetrics and Gynecology at The First Affiliated Hospital of USTC, the University of Science and Technology of China in Hefei, China.
Natural killer cells, or NK cells, are part of the innate immune system and are one of our front-line defenses against cancer. They kill tumor cells without needing prior sensitization, unlike T cells. But many cancers have evolved ways to evade NK cell killing.
This paper identifies a protein called GBP6 as a tumor-intrinsic factor that promotes immune evasion in cervical cancer. GBP6 was found to be enriched in high-risk tumors and associated with poor clinical outcomes. When GBP6 was knocked down, tumor cells proliferated less and died more.
The mechanism is centered on mitochondria. GBP6 localizes to the mitochondria and interacts with a protein called TACO1, helping to maintain the integrity and activity of respiratory complex IV, which is part of the electron transport chain that generates cellular energy. When GBP6 is depleted, mitochondrial bioenergetics collapse. Membrane potential drops, NADPH availability falls, reactive oxygen species or ROS production increases, and the cellular antioxidant system based on the GSH-GPX4 axis is compromised. This leads to lipid peroxidation and a form of cell death called ferroptosis.
Now here's the immunological punchline. This mitochondrial redox stress triggers NF-kappa-B signaling through ROS, which upregulates a molecule called ICAM-1 on the surface of the tumor cells. ICAM-1 is an adhesion molecule that helps NK cells dock onto and kill their targets. So by depleting GBP6, tumor cells become more vulnerable to NK cell killing through enhanced immune synapse formation.
In mouse models, GBP6 depletion sensitized tumors to adoptively transferred NK cells. This identifies GBP6 as a link between metabolic fitness and innate immune evasion, and a potential therapeutic target.
We also have a couple of papers on microbiology and gut health worth highlighting. One paper in Cell Reports titled Mechanistic insights into TAM-mediated OMP assembly in Gram-negative bacteria by Qinghua Luo from West China Hospital, Sichuan University in Chengdu, China, presents cryo-electron microscopy structures of a protein complex called TamAB in Escherichia coli. This complex is responsible for assembling outer membrane proteins in Gram-negative bacteria, which are bacteria with a particular cell wall structure. The structures reveal how the TamB protein opens a gate in TamA to facilitate outer membrane protein assembly through a substrate-mimetic priming mechanism. Because this machinery is essential for bacterial survival and absent in humans, it's a validated target for antibiotic development.
Also in Cell Reports, we have the paper titled Microbial metabolite hyodeoxycholic acid induces macrophage immunometabolic reprogramming and alleviates ulcerative colitis, published July 27th 2026. The first author is Yaping An from Tianjin Medical University in Tianjin, China. The team found that patients with ulcerative colitis have reduced levels of a bile acid metabolite called hyodeoxycholic acid, or HDCA, and that lower levels correlated with more severe disease. A gut bacterium called Ruminococcus callidus was linked to HDCA production via an enzyme called bile salt hydrolase. HDCA reshaped the intestinal macrophage landscape by enriching a subpopulation called Mrc1-positive macrophages with immunosuppressive features. The mechanism involved PPARgamma-mediated fatty acid metabolism reprogramming and epigenetic changes through histone acetylation. This opens a potential therapeutic avenue using HDCA to treat ulcerative colitis.
In Nature Communications, the paper titled Obesity-driven microbial GABA depletion promotes metabolic rewiring and colorectal cancer progression, published July 27th 2026, with first author Wei Guo from Shandong University in Jinan, China, shows that a high-fat diet depletes a GABA-producing gut bacterium called Bacteroides ovatus. Reduced GABA leads to impaired epithelial signaling through GABAB receptors and activates a molecular pathway involving PI3K, HIF1-alpha, TPI1, and ultimately the YAP transcription factor, which promotes tumor growth. Oral GABA supplementation or restoration of Bacteroides ovatus suppressed tumor burden, identifying a microbiota-neurotransmitter-metabolism axis linking obesity to colorectal cancer.
And one more gut-related paper from Cell Reports: Tracing NAD-plus metabolism uncovers adaptive coordination between host and microbiome during colitis, published July 25th 2026, with first author Abrar Alsaadi from Pennsylvania State University. This study examined how the metabolite NAD-plus, which stands for nicotinamide adenine dinucleotide and is essential for cellular energy production, is metabolized and shared between the host and gut microbiota during colitis. The abstract was not fully available, but the topic highlights an emerging area of research into how host-microbiota metabolic interactions regulate inflammatory bowel disease.
Also in Cell Reports, Microbial imprinting of the airway epithelium, published July 24th 2026, with first author Joyce van de Ven from Utrecht University in the Netherlands, proposes a conceptual framework for how microbes can leave lasting functional imprints on the airway epithelium through metabolic and epigenetic reprogramming. The authors describe four categories of epithelial imprinting: differentiation, tolerance, priming, and trained immunity. This is a thought-provoking perspective piece with implications for understanding and potentially harnessing microbial factors to improve respiratory health.
Now let me briefly mention some additional articles that were published without full abstracts available but are worth knowing about.
In Nature Immunology, there's a piece from July 23rd 2026 titled Industrial-scale mRNA expertise meets a century of tuberculosis immunology, authored by Galit Alter from AstraZeneca in Gaithersburg, Maryland. Given that it appears in Nature Immunology, which focuses exclusively on immunology, this is certainly worth watching. It appears to be a commentary or perspective on the intersection of mRNA vaccine technology with tuberculosis research, which is a hugely exciting development given how much COVID-19 vaccines advanced mRNA platform capabilities.
Also from Nature Microbiology on July 23rd 2026, Ebola virus persistence and the hidden cost of immune privilege, authored by Amal Fahmi from the Institute of Virology and Immunology in Bern, Switzerland. This appears to address the fascinating and troubling phenomenon of Ebola virus persisting in immune-privileged sites like the eye or testes even after apparent recovery, with implications for long-term infection management and outbreak control.
In the Journal of Experimental Medicine from August 3rd 2026, there's an addendum from Brandon Hogstad related to a previous paper titled RAF MEK extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Langerhans cell histiocytosis is a rare inflammatory disease involving abnormal dendritic cell accumulation, and this addendum updates or clarifies findings from earlier work on this topic.
From Nature on July 22nd 2026, Flora Graham published a piece in the daily briefing section asking Can the world finally eradicate polio, touching on the ongoing global public health effort to wipe out poliovirus.
From Nature on July 20th 2026, Dan Garisto reported on smuggling charges against NIH virologists that have triggered a political uproar, a news story that intersects science, law, and politics.
In Gastroenterology from July 21st 2026, there are several notable pieces: Bepirovirsen Brings Functional Cure Closer to Reality in Chronic Hepatitis B by Sabela Lens from Hospital Clinic Barcelona in Spain, which discusses progress toward curing hepatitis B using